# A Study of Xeloda (Capecitabine) in Patients With Advanced and/or Metastatic Colorectal Cancer

> **NCT00048126** · PHASE2 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 57 (actual)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** Irinotecan
- **DRUG:** capecitabine [Xeloda]

## Key facts

- **NCT ID:** NCT00048126
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-07
- **Primary completion:** 2005-01
- **Final completion:** 2005-01
- **Target enrollment:** 57 (ACTUAL)
- **Last updated:** 2016-11-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00048126

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00048126, "A Study of Xeloda (Capecitabine) in Patients With Advanced and/or Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00048126. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*